Q3 2026 Church & Dwight Earnings Conference Call - CHURCH & DWIGHT CO INC

Financial Performance:

• Net sales increased 1% (outperforming the 1% decline outlook), driven by 5.1% organic sales growth (vs. 3% outlook).
• Organic growth fueled by 4.6% volume increase and 0.5% favorable price/mix.
• Gross margin expanded 170 basis points year-over-year to 46.8%, driven by 150 bps in productivity and 160 bps from acquisition mix/portfolio actions, partially offset by 180 bps of inflation/transportation headwinds.
• Adjusted EPS reached $0.92, up 13.6% year-over-year and beating the $0.89 outlook.
• Operating income rose 10.1% to $298 million.
• Marketing spend reached 11.9% of sales; Adjusted SG&A was 16.3% of sales (up 110 bps YoY) due to acquisition amortization and growth investments.
• First nine months cash from operations totaled $841 million with a 114% conversion rate; full-year capex expected at ~$125 million (2% of sales).
• Total debt stood at $2.2 billion with $447 million in cash; Board authorized a new indefinite $1 billion share repurchase program.

Guidance and Future Outlook:

• Raised full-year 2026 organic sales growth guidance to approximately 5% (top of previous 4-5% range).
• Tightened 2026 Adjusted EPS guidance to approximately 7% (up from 6-8% range), reflecting strong YTD performance.
• Q4 2026 outlook: Organic sales growth of ~4% and Adjusted EPS growth of 17-19%.
• Full-year 2026 Outlook includes ~$150 million in inflation costs (driven by crude oil at ~$100/barrel and transportation rates), up from prior estimates.
• Expects gross margin to expand ~100 basis points for the full year despite headwinds, assuming marketing remains at ~11% of sales.
• Long-term optimism for 2027 and beyond, driven by record productivity expected in 2027, fixed cost leverage, and the rollout of 2030 growth initiatives (Arm & Hammer expansion, TheraBreath global scale, international growth).
• Plans to announce specific 2030 growth initiative details at the January Analyst Day.

Business Segments and Product Lines:

• U.S. Consumer Business: Organic sales +4.4%; led by Arm & Hammer Liquid Laundry Detergent (record share, >4% consumption growth), Cat Litter (5.4% consumption growth, 24% share), TheraBreath Mouthwash (+3.5 share points to record 26.8% share), TheraBreath Toothpaste, Hero acne cleansers (launch expanding share), and Waterpik (double-digit growth).
• Touchland: Q3 U.S. growth slowed due to competition; expected to be flat for the full year. International launches in UK/Australia showing excellent early results; broad US distribution expansion and beauty class-of-trade entry planned for 2027-2028.
• International: Organic sales +7.8% driven by 9.1% volume growth; led by TheraBreath, Batiste, Touchland, and OxiClean (nine brands with double-digit growth).
• Specialty Products Division (SPD): Organic sales +5.0% (2.9% volume, 2.1% price/mix), marking the 11th consecutive quarter of growth.
• E-commerce: Global online sales grew 20% to represent 25.9% of total consumer sales.
• Innovation: 26 new innovations across power brands performing well; Hero acne cleanser launch gaining traction; TheraBreath gaining global distribution (e.g., Japan).

Market and Competitive Landscape:

• Overall category growth projected at ~2.5% for 2026 and 2027, up from early-year 2% expectations.
• Arm & Hammer gained share in laundry and litter despite elevated promotional activity in the category.
• TheraBreath has reached a number 2 position in mouthwash, closing in on Listerine; household penetration remains low (14% vs. category 65%), indicating significant runway.
• Touchland is viewed as creating a new category in beauty; current competition is limited, but growth is accelerating internationally and with new US distribution.
• Company reports second-highest TDP (Trade Development Program) growth in the industry for 2026.

Risks and Challenges:

• Inflationary pressures from Middle East conflict and rising global transportation rates (estimated $150 million impact for 2026).
• Elevated promotional levels in household categories (e.g., laundry) compared to historical norms.
• Slowing growth for Touchland in the U.S. due to new competitive entrants.
• Structural driver shortages leading to potential persistent transportation cost increases.
• Currency exchange (FX) impacts on price/mix.

Management Commentary and Tone:

• Tone was highly confident and optimistic, emphasizing "execution excellence" in a volatile environment.
• Management highlighted a "relentless focus on innovation" and "broad-based growth" across all divisions.
• Emphasized that innovation is a core competency, with a "good, better, best" strategy deployed across household and personal care.
• Expressed strong confidence in the ability to maintain margin expansion through productivity (record levels expected in 2026 and 2027) and Revenue Growth Management (RGM) tools.
• Management noted that while 2026 reported sales growth was flat due to prior divestitures, 2027 will see convergence of organic and reported numbers, providing operating leverage.

Analyst Questions and Answers:

• Innovation & Value: Management confirmed innovation strategies extend to value tiers, intersecting value and price rather than just lowering prices.
• Gross Margin 2027: Drivers include record productivity, RGM toolkit, favorable mix from innovation, and fixed cost leverage; hedging is currently slightly more aggressive than prior year.
• Category Trends: Management is bullish on categories (2.5% growth) and noted Q4 trends are strong, with 4% guidance being conservative.
• Touchland Outlook: Full year expected flat, but strong Q4 growth anticipated and international/international distribution expansion expected to drive 2027 growth.
• TheraBreath Runway: Significant growth potential remains due to low household penetration and global expansion (including Japan); toothpaste repeat rates are approaching 30%.
• M&A Strategy: Criteria remain focused on #1/#2 brands and asset-light models, with increased flexibility for international acquisitions (e.g., accepting full back-office structures).
• Hedging & Commodities: WTI crude benchmark used for oil; slightly more hedged than prior year, though the overall inflation bucket is larger.
• Licensing/Reacquisition: One brand already reacquired; 2-3 additional candidates under review to meet internal thresholds, with updates expected at the January Analyst Day.

Other Key Points:

• A new $1 billion share repurchase program with no expiration date was approved to replace the expiring 2021 authorization.
• The company shed $400 million of businesses in prior years, contributing to the 2026 reported sales stagnation, but will provide leverage in 2027.
• International M&A diligence has shifted from US-centric to a broader global scope.
• Tariff refunds provided a net benefit of ~$15 million in Q3 and ~$5 million expected in Q4, included within the inflation outlook.
• Management reiterated commitment to an "evergreen model" of gross margin expansion as the core financial lifeblood of the organization.